Psoriasis is a chronic, immune-driven condition in which skin cells renew far faster than normal. It most often appears on the elbows, knees, scalp and lower back as red, thickened plaques topped with silvery scale. It is not contagious; it runs in flares and quieter spells, and its severity varies widely from one person to another.
Both genetic predisposition and triggers shape the course of the disease. Stress, throat infections, certain medicines, smoking, alcohol and skin injury can set off flares. Psoriasis is not limited to the skin either; because it can occur alongside joint involvement, nail changes and metabolic problems, a whole-person assessment matters a great deal.
At Clinovia our approach is cortisone-free by default. In milder cases we use calcineurin and PDE-4 inhibitors with ceramide barrier repair; in more widespread disease we move to 311 nm NB-UVB phototherapy. For resistant cases, screening is followed by IL-17 or IL-23 targeted biologics or monitored systemic therapy. We measure response with PASI and DLQI.
Beyond the skin, we also review systemic factors: vitamin D, zinc, iron, thyroid function and insulin resistance, along with gut barrier health, are linked to how psoriasis behaves. The aim is not to suppress plaques briefly but to reduce triggers and build durable, sustainable control. We offer our services in five languages and shape the plan around each patient.